Status:
COMPLETED
Special Drug Use-results Surveillance of Scemblix Tablets
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
Up to 99 years
Brief Summary
Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.
Detailed Description
The objective of this study is to collect data on the occurrence, severity, clinical courses of the safety specifications of asciminib, identify factors etc. involved in occurrence and assess its clin...
Eligibility Criteria
Inclusion
- patients treated with asciminib in Japan.
Exclusion
- NA
Key Trial Info
Start Date :
July 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 29 2024
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT05421091
Start Date
July 4 2022
End Date
February 29 2024
Last Update
March 27 2024
Active Locations (278)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Anjo, Aichi-ken, Japan, 446-8602
2
Novartis Investigative Site
Ichinomiya, Aichi-ken, Japan, 491-0041
3
Novartis Investigative Site
Kasugai, Aichi-ken, Japan, 486-8510
4
Novartis Investigative Site
Komaki, Aichi-ken, Japan, 485-8520